Effect of probucol treatment on lipoprotein cholesterol and drug levels in blood and lipoproteins in familial hypercholesterolemia
| Autor: | Giorgio Crepaldi, G. Valerio, Giovannella Baggio, E. Vitale, M.R. Baiocchi, A. Gasparotto, S. Lamon, Renato Fellin, Roberto Padrini |
|---|---|
| Rok vydání: | 1986 |
| Předmět: |
Adult
Male medicine.medical_specialty Very low-density lipoprotein Apolipoprotein B Probucol Familial hypercholesterolemia Lipoproteins VLDL Placebo Hyperlipoproteinemia Type II chemistry.chemical_compound Phenols Pharmacokinetics Internal medicine Humans Medicine Apolipoproteins A Apolipoproteins B Apolipoprotein A-I biology Cholesterol business.industry Cholesterol HDL Lipoproteins HDL3 Cholesterol LDL Middle Aged medicine.disease Lipoproteins HDL2 Lipoproteins LDL Endocrinology chemistry biology.protein Female lipids (amino acids peptides and proteins) Lipoproteins HDL Cardiology and Cardiovascular Medicine business Lipoprotein medicine.drug |
| Zdroj: | Atherosclerosis. 59:47-56 |
| ISSN: | 0021-9150 |
| DOI: | 10.1016/0021-9150(86)90032-8 |
| Popis: | Twelve patients with mild and 3 with severe hypercholesterolemia were stabilized with an isocaloric diet containing less than 300 mg cholesterol daily with a P/S ratio of 1.8, and placebo period of 4 weeks. They were administered 1000 mg probucol daily for 12 weeks, followed by placebo for 6 weeks. In patients with mild disease, a significant cholesterol reduction was achieved in serum, LDL, and HDL (maximum decrease, 17%, 13%, and 31%, respectively). While HDL3 cholesterol was reduced significantly throughout the period (P less than 0.001), HDL2 cholesterol showed a significant decrease only at the 4th week of treatment (P less than 0.001), and returned to basal levels at the 8th and 12th treatment weeks. Serum apo B levels decreased only slightly, but the HDL-apo A-I fall was significant with a reduction in the HDL-CH/HDL-apo A-I ratio throughout the treatment period. In 3 patients with severe disease, cholesterol decrease in serum and in VLDL, LDL and HDL fractions varied, but on the whole was lower than in patients with mild disease. A decrease in VLDL-CH and HDL-CH was present in all 3, but LDL-CH levels were only slightly lowered in 2 patients, and unchanged in the third. Serum probucol levels fell 66% from the 4th to the 12th treatment week, and in parallel, the percentage of lipoprotein-bound drug increased about 2-fold. It is suggested that these changes in pharmacokinetics as well as the cholesterol-lowering effect of the drug may be due to a change in lipoprotein composition or structure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|